Redefining what’s possible in cystic fibrosis treatment

Our vision is to fully normalize CFTR function

Who We Are

We are a clinical-stage company on a mission to develop highly effective and differentiated treatments for cystic fibrosis (CF) to normalize the function of CFTR, the key protein associated with the disease. We are advancing a pipeline of small molecules engineered to correct the defects caused by F508del, the most common CF mutation, which resides in the nucleotide-binding domain 1 (NBD1) of CFTR. Our first-in-class programs directly target NBD1, which we believe is the key mechanism to enable full CFTR correction. We’re also advancing complementary programs that target ICL4 and TMD1, two other important domains of the CFTR protein affecting CF.

We believe this pipeline has the potential to deliver best-in-class options for CF patients and set a new standard of care in CF.

Latest News

November 18, 2024
Sionna Therapeutics Announces Appointment of Laurie Stelzer to its Board of Directors
Read more
August 13, 2024
Sionna Therapeutics Announces Initiation of Two Phase 1 Clinical Trials of SION-719 and SION-451, in Development for Cystic Fibrosis
Read more
July 16, 2024
Sionna Therapeutics Expands Pipeline with Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement with AbbVie
Read more